| P50 | author | Helge Karch | Q1602385 |
| | Klaus Dreisewerd | Q30510255 |
| | Jörg Haier | Q87717947 |
| | Norbert Senninger | Q91657166 |
| | Jamal Souady | Q114422050 |
| | Irena Drmić-Hofman | Q114422051 |
| | Stefan Berkenkamp | Q114422052 |
| | Jasna Peter-Katalinić | Q34579837 |
| | Ute Distler | Q34579895 |
| | Johannes Müthing | Q34579914 |
| | Marcel Hülsewig | Q34580195 |
| P2093 | author name string | M Alexander Schmidt | |
| | Alexander W Friedrich | |
| P2860 | cites work | The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1 | Q24563989 |
| | Cancer statistics, 2008 | Q27860585 |
| | Functional rafts in cell membranes | Q27860768 |
| | Raft trafficking of AB5 subunit bacterial toxins | Q28271528 |
| | Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. | Q54454112 |
| | Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance | Q57374107 |
| | 1H-n.m.r. analysis of type-2 chain lacto-gangliosides. Confirmation of structure of a novel cancer-associated fucoganglioside, alpha-NeuAc-(2----6)- beta-D-Galp-(1----4)-beta-D-GlcpNAc-(1----3)-beta-D-Galp-(1----4)-[alp ha-L- Fucp-(1----3)]-beta-D-G | Q67969077 |
| | Novel fucolipids accumulating in human adenocarcinoma. I. Glycolipids with di- or trifucosylated type 2 chain | Q71300760 |
| | A Sphingolipid Having a Novel Type of Ceramide and Lacto-N-Fucopentaose III | Q71760939 |
| | Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma | Q73666501 |
| | Shiga toxins | Q74609189 |
| | Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells | Q77336741 |
| | Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity | Q40028252 |
| | Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model | Q40047881 |
| | A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. | Q40272721 |
| | Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. | Q40304198 |
| | New insights into the role of Shiga toxins in intestinal disease | Q40361088 |
| | Role of verotoxin receptors in pathogenesis | Q41052833 |
| | Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism | Q41270282 |
| | Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues | Q41474149 |
| | Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. | Q42065084 |
| | Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens | Q43890454 |
| | Effect of globotriaosyl ceramide fatty acid alpha-hydroxylation on the binding by verotoxin 1 and verotoxin 2. | Q44175475 |
| | Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool | Q46440038 |
| | Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shig | Q46801673 |
| | Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. | Q47622602 |
| | The transmissible nature of enterotoxin production in a human enteropathogenic strain of Escherichia coli | Q47740974 |
| | TLC in structure and recognition studies of glycosphingolipids | Q47845556 |
| | In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. | Q53528575 |
| | The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer | Q33229926 |
| | Glycosphingolipid structural analysis and glycosphingolipidomics | Q33231658 |
| | Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer | Q33320050 |
| | Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. | Q33326649 |
| | Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer | Q33362834 |
| | Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome | Q33365488 |
| | Enterohaemorrhagic Escherichia coli in human medicine | Q33368999 |
| | The continuing evolution of a bacterial pathogen | Q33379025 |
| | Shiga toxins, glycosphingolipid diversity, and endothelial cell injury | Q33383102 |
| | Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. | Q33891183 |
| | The cluster glycoside effect | Q34113785 |
| | Biology and management of pancreatic cancer | Q34649019 |
| | Shiga toxin induces tubular membrane invaginations for its uptake into cells | Q34719609 |
| | The treatment of malignant meningioma with verotoxin | Q34929060 |
| | Gangliosides as therapeutic targets for cancer | Q35128665 |
| | Glycosphingolipids as toxin receptors | Q35811143 |
| | An overview of adjuvant systemic chemotherapy for colon cancer. | Q35814568 |
| | Protein toxins: intracellular trafficking for targeted therapy. | Q36132002 |
| | (Patho-)Genomics of Escherichia coli. | Q36291964 |
| | Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. | Q36505386 |
| | Ribosome-inactivating proteins: progress and problems. | Q36519065 |
| | Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants--Hakomori's concepts revisited | Q36991074 |
| | Surgical therapy for colorectal adenocarcinoma | Q37099653 |
| | Novel binding epitope for Helicobacter pylori found in neolacto carbohydrate chains: structure and cross-binding properties | Q38329815 |
| | Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. | Q38334780 |
| | Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity | Q39958619 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreas | Q9618 |
| | colon cancer | Q18555025 |
| P304 | page(s) | e6813 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer | |
| P478 | volume | 4 | |